Olema Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2021-12-10

Reporting Person: Horn Kinney (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-10	Common Stock	M	5251	$2.064	Acquired	7709	Direct
2021-12-10	Common Stock	S	5251	$10.39	Disposed	2458	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-10	Stock Option (Right to Buy)	$2.064	M	5251	Disposed	2030-06-09	Common Stock (5251)	Direct

Footnotes

F1: Includes 668 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.

F2: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F3: The weighted average sale price for the transaction reported was $10.39, and the range of prices were between $10.18 and $11.11. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F4: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.